Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort

Author Urueta-Robledo, Juan Google Scholar
Ariza, Horacio Google Scholar
Jardim, José Roberto Autor UNIFESP Google Scholar
Caballero, Andres Google Scholar
Garcia-Calderon, Andres Google Scholar
Amabile-Cuevas, Carlos F. Google Scholar
Hernandez-Oliva, Gerardo Google Scholar
Vivar-Orozco, Raul Google Scholar
MOX-CB Study Group Google Scholar
Institution Fdn LUSARA
Inst Nacl Enfermedades Resp
Hosp Mi Pueblo
Universidade Federal de São Paulo (UNIFESP)
Clin Reina Sofia
Clin Ricardo Palma
Bayer Mexico
Abstract We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized to oral therapy with either moxifloxacin 400 mg once daily for 5 days or levofloxacin 500 mg once daily for 7 days. Clinical success was achieved in 201 out of 221 (91.0%) patients in the moxifloxacin group, and in 203 out of 216 (94.0%) in the levofloxacin group, indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic eradication or presumed eradication was also similar in the two treatment groups: 92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the most common drug-related adverse event in each treatment group. the rate of discontinuation because of adverse events was very low (<= 2%). in conclusion, a 5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day course of levofloxacin in the treatment of patients with AECB. the short treatment duration with moxifloxacin may have compliance advantages over other currently used therapies in the 'real-Life' clinical setting. (c) 2006 Elsevier B.V. All rights reserved.
Keywords chronic bronchitis
moxifloxacin
levofloxacin
Language English
Date 2006-09-01
Published in Respiratory Medicine. London: W B Saunders Co Ltd, v. 100, n. 9, p. 1504-1511, 2006.
ISSN 0954-6111 (Sherpa/Romeo, impact factor)
Publisher W B Saunders Co Ltd
Extent 1504-1511
Origin http://dx.doi.org/10.1016/j.rmed.2006.01.013
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000239833900003
URI http://repositorio.unifesp.br/handle/11600/29103

Show full item record




File

Name: WOS000239833900003.pdf
Size: 102.9Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account